Antiandrogen withdrawal syndrome with nilutamide.

[1]  N. Dawson,et al.  Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. , 1995, The Journal of urology.

[2]  J. Moul,et al.  Molecular implications of the antiandrogen withdrawal syndrome. , 1995, Seminars in urology.

[3]  O. Sartor,et al.  Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. , 1995, The American journal of medicine.

[4]  E. Crawford,et al.  Case Reports: Withdrawal Phenomenon With the Antiandrogen Casodex , 1995 .

[5]  P. Nieh.  Withdrawal phenomenon with the antiandrogen casodex. , 1995, The Journal of urology.

[6]  P. Carroll,et al.  Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. , 1994, Urology.

[7]  M. Koutsilieris,et al.  Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. , 1993, The Journal of urology.

[8]  H. Scher,et al.  Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Veldscholte,et al.  Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[10]  M. Chen,et al.  Aberrant response in vitro of hormone‐responsive prostate cancer cells to antiandrogens , 1989, The Prostate.